Prophylaxis, Monitoring & Management of Dato-DXd associated Adverse Events

Stomatitis and Mucositis Management with Dato-DXd

PROPHYLAXIS

Initiate daily oral care plan prior to administration of first Dato-DXd dose

- **Gentle brushing** of teeth after meals and at bedtime using a soft toothbrush and a bland fluoride-containing toothpaste **Daily flossing**, unless it causes pain or bleeding
- **Daily use of a corticosteroid-containing mouthwash,** e.g., dexamethasone oral solution 0.1 mg/mL (10 mL, 4 times daily, swish for 1-2 minutes then spit out), or a similar mouthwash regimen using an alternative steroid advocated by institutional/local clinical practice guidelines is highly recommended; an oral nystatin suspension, or other topical antifungal agents, may be considered ≥15 minutes after the steroid-containing mouthwash.
- **Consider cryotherapy** (ie, ice chips or ice water held in mouth) during infusions
- **Education on the importance of oral hygiene**, hydration and lubrication of the oral mucosa and adherence to oral care plan

MONITOR

- **Stomatitis** often occurs earlier during the course of Dato-DXd therapy but can occur at anytime throughout treatment
- Regular oral exams by oncology care team to **detect mucositis** early
- **Oral sensitivity, inflammation and tenderness** of the oral mucosa can occur without the appearance of sores

MANAGE[a]

SUPPORTIVE CARE

- **Increase frequency of mouthwash** to up to every hour, if necessary
- **Use steroid-containing mouthwash** as soon as oral pain, inflammation, or ulceration develops
- **Provide pain management** (lidocaine-based mouthwash, topical clobetasol gel)
- **Consider referral to a dentist,** oral surgeon, oral medicine expert, or dermatologist for severe or persistent events

DOSE MODIFICATIONS

GRADE 1: Maintain dose, optimise prophylactic and supportive medications

GRADE 2: Consider a dose delay or reduction if not resolved

GRADE 3:
- **If prophylaxis and supportive medications have not yet been optimised,** delay dose until resolved to grade ≤1 or baseline, optimise medications, and then maintain dose
- **If prophylaxis and supportive medications have already been optimised,** delay dose until resolved to grade ≤1 or baseline, then reduce the dose by 1 level

GRADE 4: Discontinue Dato-DXd

Dato-DXd dose reduction schedule: starting dose = 6.0 mg/kg; 1st reduction = 4.0 mg/kg; 2nd reduction = 3.0 mg/kg; 3rd reduction (for patients with lung cancer only) = 2.0 mg/kg; if further dose reduction required = discontinue treatment

[a]NCI CTCAE version 5.0 grading

Dato-DXd, datopotamab deruxtecan; NCI CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events

References: Lisberg A, et al. Oncologist 2025; 30:oyaf225. doi: 10.1093/oncolo/oyaf225;
Meric-Bernstam F, et al. Oncologist 2025; 30:oyaf031. doi: 10.1093/oncolo/oyaf031

COR2ED
THE HEART OF MEDICAL EDUCATION

Go to COR2ED.COM for more information and resources